Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clindamycin Hydrochloride

FDA-approved product (capsule, oral), marketed as Cleocin, Cleocin Hydrochloride, Clindamycin Hydrochloride.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clindamycin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Bacterial disease
  • Endometritis
  • Infection
  • Osteomyelitis
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives for treatment of acne; Antibiotics; Lincosamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF01; WHO ATC J01FF01; WHO ATC G01AA10

Repurposing investigation

Clindamycin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis4.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 4 lab records
Open Clindamycin Hydrochloride in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clindamycin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Taste of Medicines in Children

    NCT04220918 · start 2020-02-14

    Registered record
    Registry ID
    NCT04220918
    Conditions
    Medication Adherence; Medication Reaction
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-02-14
    Completion
    2023-02-01
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedication Adherence; Medication Reaction
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Topical Sinonasal Antibiotics

    NCT03935828 · start 2019-06

    Registered record
    Registry ID
    NCT03935828
    Conditions
    Chronic Rhinosinusitis (Diagnosis); Antibiotic Side Effect
    Interventions
    Oral versus topical antibioitics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-06
    Completion
    2021-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis (Diagnosis); Antibiotic Side Effect
    InterventionOral versus topical antibioitics
    PhasePhase 2
    Registry statusWithdrawn

  • Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

    NCT04134273 · start 2019-03-20

    Registered record
    Registry ID
    NCT04134273
    Conditions
    Acne Vulgaris
    Interventions
    CLPG Topical Gel 1%; Clindamycin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-03-20
    Completion
    2019-10-15
    Enrolment
    1,260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionCLPG Topical Gel 1%; Clindamycin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Duration of IM Injection and Pain Intensity

    NCT05822336 · start 2019-03-01

    Registered record
    Registry ID
    NCT05822336
    Conditions
    Pain Measurement
    Interventions
    Duration of Intramuscular Injections
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-03-01
    Completion
    2021-05-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain Measurement
    InterventionDuration of Intramuscular Injections
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting

  • Does Antibiotic Prophylaxis Reduce Wound Complications After Vulvar Excision of Premalignant Lesions

    NCT03578965 · start 2018-07-13

    Registered record
    Registry ID
    NCT03578965
    Conditions
    Premalignant Vulvar Lesion; Benign Vulvar Lesion
    Interventions
    Cefazolin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-07-13
    Completion
    2021-11-23
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremalignant Vulvar Lesion; Benign Vulvar Lesion
    InterventionCefazolin
    PhasePhase 2
    Registry statusCompleted

  • Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients

    NCT03742908 · start 2018-06-16

    Registered record
    Registry ID
    NCT03742908
    Conditions
    Breast Neoplasms
    Interventions
    Cefazolin/clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-06-16
    Completion
    2021-10-31
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionCefazolin/clindamycin
    PhaseNot applicable
    Registry statusUnknown

  • Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

    NCT02814916 · start 2017-03-30

    Registered record
    Registry ID
    NCT02814916
    Conditions
    Methicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections
    Interventions
    Dalbavancin; Vancomycin; Oxacillin; Flucloxacillin; Cefadroxil; Clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-30
    Completion
    2024-01-01
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections
    InterventionDalbavancin; Vancomycin; Oxacillin; Flucloxacillin +2 more
    PhasePhase 3
    Registry statusCompleted

  • Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study

    NCT02795845 · start 2016-11

    Registered record
    Registry ID
    NCT02795845
    Conditions
    Bacterial Vaginosis and Vaginal Candidiasis At Pregnancy
    Interventions
    Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-11
    Completion
    2021-08
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Vaginosis and Vaginal Candidiasis At Pregnancy
    InterventionProbiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Vaginal Clindamycin Cream Plus Vaginal Probiotic for Bacterial Vaginosis

    NCT03234517 · start 2016-08-01

    Registered record
    Registry ID
    NCT03234517
    Conditions
    Bacterial Vaginosis Treatment
    Interventions
    Vaginal Clindamycin Cream; Vaginal Probiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-08-01
    Completion
    2018-08
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Vaginosis Treatment
    InterventionVaginal Clindamycin Cream; Vaginal Probiotic
    PhasePhase 2
    Registry statusUnknown

  • Antibiotics and Tissue Expanders in Breast Reconstruction

    NCT01899690 · start 2016-06

    Registered record
    Registry ID
    NCT01899690
    Conditions
    Complications; Breast Prosthesis, Infection or Inflammation
    Interventions
    antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2016-06
    Completion
    2017-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplications; Breast Prosthesis, Infection or Inflammation
    Interventionantibiotic
    PhasePhase 4
    Registry statusWithdrawn

  • Aspiration Treatment of Perianal Abscess

    NCT02585141 · start 2015-10

    Registered record
    Registry ID
    NCT02585141
    Conditions
    Anal Fistulas
    Interventions
    MEDIPLAST® (aspiration); incision; Clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-10
    Completion
    2020-06
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnal Fistulas
    InterventionMEDIPLAST® (aspiration); incision; Clindamycin
    PhaseNot applicable
    Registry statusCompleted

  • To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

    NCT02465632 · start 2015-04

    Registered record
    Registry ID
    NCT02465632
    Conditions
    Acne Vulgaris
    Interventions
    Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel; BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-04
    Completion
    2015-12
    Enrolment
    1,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionClindamycin 1%/Benzoyl Peroxide 5% Topical Gel; BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne

    NCT02593383 · start 2015-03-01

    Registered record
    Registry ID
    NCT02593383
    Conditions
    Acne
    Interventions
    Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-03-01
    Completion
    2017-07-31
    Enrolment
    245

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne
    InterventionAdapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted